Interleukín-13: nový cieľ biologickej liečby atopickej dermatitídy // SOLEN

Dermatológia pre prax 4/2025

Interleukin-13: a new target for biological treatment of atopic dermatitis

The pathogenesis of atopic dermatitis (AD) is crucially influenced by two main factors: dysregulation of the immune response and epidermal barrier dysfunction. In the lesional skin of atopic dermatitis various immune cells, including Th2 cells, type 2 innate lymphoid cells (ILC2s), mast cells and basophils, produce several type 2 cytokines [interleukin (IL)-4, IL-5, IL-13, IL-31]. Out of these, IL-13 is considered to be the major player in the pathogenesis of the disease. Searching for new and more selective treatments for moderateto-severe cases is important because of the considerable effect of AD on the quality of life. Tralokinumab and lebrikizumab are new selective IL-13 inhibitors that have demonstrated safety and efficacy as treatment options for AD.

Keywords: atopic dermatitis, interleukin-13, tralokinumab, lebrikizumab